跳至主要内容
临床试验/TCTR20210623004
TCTR20210623004招募中2 期

Postoperative hypofractionation and simultaneous integrated boost with or without regional nodal irradiation by TomoTherapy for breast cancer

/A0 个研究点目标入组 48 人开始时间: 2021年6月23日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
Female

入选标准

  • 1. Received breast conserving surgery (BCS)
  • 2. With or without the indication for regional nodal irradiation (RNI)
  • 3. Pathologically confirmed breast cancer
  • 4. Free surgical margins from both invasive carcinoma and ductal carcinoma in situ (DCIS)
  • 5. Indication for tumor bed boost according institutional protocol
  • (age < 50 years or age > 50 years with high risk features)
  • 6. Clearly identified primary tumor region preferably by radiopaque clips
  • 7. Surgical wound healing without signs of infection
  • 8. Age 18 years old or more
  • 9. ECOG performance status 0-1
  • 10. Written informed consent
  • 11. Compliance regarding to follow up

排除标准

  • 1. Patients received mastectomy
  • 2. No indication for boost radiation
  • 3. Inadequate identification of the boost volume
  • 4. Bilateral breast cancer
  • 5. History of prior breast or thoracic radiotherapy
  • 6. Extended postoperative seroma at the beginning of radiotherapy
  • 7. Pregnant or lactating patients
  • 8. Treatment history of other cancer
  • 9. Patients with serious, uncontrolled, physical or cerebrovascular disorders

研究者

发起方
/A

相似试验

Postoperative hypofractionation and simultaneous... | 临床试验